The present invention relates to a needle-free delivery solution for delivering drugs and vaccines applied in the field of human
clinical care and
animal health care, including a needle-free delivery device and components thereof, a
system, and a related
drug-instrument
combination product. By means of the arrangement of multiple pores and the control of the flow rate of the
jet flow of drugs and vaccines, the dispersion degree of drugs and vaccines
in vivo, the number of pores, the pore size, and the distribution of the pores, the present invention can significantly improve the single-
dose delivery amount of drugs and vaccines without damaging the
skin, has a
delivery efficiency far higher than that of existing needle-free injections, and can be applied to a wider range of application scenarios. The present invention can also accurately deliver drugs and vaccines to one or more target sites at different depths in the intracutaneous tissues, subcutaneous tissues, muscles, or human organs and enhance the dispersion effect at the target sites. The present invention can also precisely control the three-dimensional dispersion degree of drugs and vaccines at the target sites, and particularly, control and regulate the dispersion volume, the dispersion range, and the dispersion center position of drugs and vaccines at the target sites, thereby greatly improving the contact effect of drugs and vaccines with the in-vivo tissues and the
bioavailability of drugs and vaccines. The needle-free delivery solution of the present invention exhibits a significantly improved
drug absorption effect, effectiveness, and a significantly enhanced vaccine
response effect in
drug-instrument combination use with a feline triple vaccine, a human
hepatitis B vaccine, a human pneumonia vaccine, a
human tumor vaccine, and
semaglutide, and especially after the vaccine is injected at an amount of 60% of a standard
dose, the average
antibody titer of the vaccine is 1.1 or more times that of a needle injection at a 100% standard
dose, and 60 days after the second dose of the vaccine is injected, the average
antibody titer can reach up to 6.3 or more times that of the average
antibody titer of the needle injection. Therefore, a novel needle-free delivery solution featuring high efficiency, precision, and excellent
bioavailability is provided for drug and
vaccine delivery. This invention relates to a needle-free jet technology for the delivery of drugs and vaccines in the field of human and
animal health,including needle-free delivery devices and their components,systems,and related drug-device combination products.By changing
nozzle settings such as the number of pores,the size of pores,and the distribution of pores,the invention controls the jet rate and the dispersion of drugs and vaccines in the body,therefore achieves better efficiency compared to the traditional needle-based delivery method,and significantly increases quantities
deliverable in a single dose without damaging the
skin.The invention can accurately deliver drugs and vaccines to target depths in the
skin,subcutis,
muscle,or organs with enhanced dispersion of drugs and vaccines at the target depth.The invention can also accurately control the three-dimensional dispersion of drugs and vaccines at the target position.Through controlling and regulating the dispersion volume,dispersion area,and dispersion epicenter,the invention greatly improves the
bioavailability of drugs and vaccines in the body.The needle-free jet delivery solution of this invention has been used in delivering multivalent cat vaccines,GLP-1 drugs,human
hepatitis B vaccines,and
human cancer vaccines in animal models.The drug-device combination of a polypeptide vaccine with the device shows significantly improved drug absorption and
immunogenicity.For the commercially available polyvalent cat vaccine from Zoetis,60%of the standard dose was combined with the needle-free jet device,generating 1.1 times the average
antibody titer of the standard dose using traditional needle-based injections.When a standard dose was combined with the needle-free jet device,the average
antibody titer 60 days after the second dose of the vaccine reached up to 6.3 times the average
antibody titer for the standard dose using traditional needle-based injection.The invention provides a new needle-free jet delivery solution with high
efficacy,accuracy,and bioavailability for drugs and vaccines.